Tracer library / [68Ga]Ga-FAP-2286

Structure of FAP-2286 (unlabelled parent compound, from PubChem) — Unlabelled parent compoundPubChem CID 163408889

[68Ga]Ga-FAP-2286

Also written as [68Ga]Ga-FAP-2286; [Ga-68]Ga-FAP-2286; FAP-2286; Ga-68 FAP-2286

Radionuclide: Ga-68 t½ 67.71 min
Modality: PET
Production route: —
Stage: —
Syntheses indexed: 2

Hepatobiliary and pancreatic cancer Lung cancer Radiochemistry methodology FAP-directed radioligand therapy

What it is

Compound class: FAP-binding peptide conjugate (peptide-based FAP inhibitor radiopharmaceutical)
Target / mechanism: Fibroblast activation protein (FAP) PMID 34168013
Clinical application: PET imaging of FAP-expressing tumors, including treatment response assessment after 177Lu-FAP-2286 therapy PMID 39338305
Theranostic pair: [177Lu]Lu-FAP-2286

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Scintomics GRP / GRP-3V Scintomics	vendor cassette	SPE	71.8 ± 1.9% decay-corrected	96.2 ± 1.2%	FAP-2286 MedChemExpress	39338305 2024 Pharmaceuticals (Basel) The synthesis was performed using a Scintomics GRP-3V module - corresponding to an average decay-corrected yield of 71.8 ± 1.9% based on the initial gallium-68 activity measured before starting the synthesis
Manual synthesis	—	SPE	69 ± 4% decay-corrected	98.9 ± 0.7%	FAP-2286 Nanchang Tanzhen Biological Technology Co., Ltd., China	41764676 2026 EJNMMI Radiopharm Chem Radiolabeling of 68Ga with DOTA-TATE, Pentixafor and FAP-2286 was performed manually using a similar operating procedure - 69 ± 4%

Clinical literature

Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.

Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results.
2022 · J Nucl Med · Prospective
Comparative 18 F-FDG PET/CT and FAP-targeted PET/CT Findings in Parotid Warthin Tumor.
2026 · Clin Nucl Med · Clinical study
177 Lu-FAP-2286 Therapy for Advanced Lung Adenocarcinoma With Multiple Metastases : A Promising Last-line Treatment Option.
2026 · Clin Nucl Med · Clinical study
Preclinical study and first-in-human imaging of [18F]FAP-2286, and comparison with 2-[18F]FDG PET/CT in various cancer patients.
2024 · Eur J Nucl Med Mol Imaging · Clinical study

Precursor

Common precursor: —
Suppliers seen in the literature: —
Cited suppliers in indexed syntheses: MedChemExpress, Nanchang Tanzhen Biological Technology Co., Ltd.
Typical final purification: —

Need this precursor?We can point you to suppliers for [68Ga]Ga-FAP-2286, or handle the enquiry for you.

Get in touch

Quality control Preliminary - inferred from compound class

Ph. Eur. monograph: not verified No Ph. Eur. check is recorded for this entry.
USP monograph: not verified No USP check is recorded for this entry.

AppearancepHRCP HPLCHPLC UVRadionuclidic (HPGe)Half-lifeActivityEndotoxins (LAL)SterilityFilter integrityMolar activityMetal impuritiesGe-68 breakthrough

How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); radiometal tracer -> metal impurities (rule); Ga-68, generator production assumed (no synthesis data found) -> Ge-68 breakthrough (preliminary); receptor ligand with a saturable target -> molar activity (rule)

Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived

Setting up quality control?We can help you scope the equipment needed to release [68Ga]Ga-FAP-2286.

Get in touch

Notes

Added from reverse module search (stage 6); 8 article(s) with Ga-68. Also seen with F-18[1] (too few articles for own row).